1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
609BA7C0200FABBA485257F730052DC68
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-internal-thought-leader-management-responsibilities-resource-allocation?opendocument
18
19opendocument
2034.235.143.190
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Thought Leader Services

Internal Thought Leader Management: Responsibilities and Resource Allocation

ID: 5404


Features:

13 Info Graphics

23 Data Graphics

250 Metrics

6 Narratives


Pages/Slides: 47


Published: 2016


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Internal Thought Leader Management: Responsibilities and Resource Allocation"

STUDY OVERVIEW

As the pharmaceutical industry has grappled with a changing marketplace marked by transparency requirements and restricted access, pharma leaders have recognized one way to successfully navigate this new landscape is to effectively establish and maintain relationships with thought leaders.

Paramount to this effort is having in place internal policies and practices that are focused on effectively managing these critical relationships. To help medical affairs leaders better understand how the industry is adjusting its approach to organizing, staffing and managing thought leader relationships, Best Practices, LLC conducted a benchmark study built to address these issues.

The study provides insights and benchmarks that illustrate how leading pharma and biotech companies organize their thought leader management as well as the activities essential to building and maintaining effective relationships. In addition, the study examines resource levels for thought leader management groups and strategies to improve internal communication and coordination of thought leader information exchange.

This study will inform medical affairs leaders on current trends and practices on these issues. Data in this study is presented in segments by company size and global vs. US only.


KEY TOPICS

  • Thought Leader Management Leadership and Responsibilities
  • Thought Leader Management Spend and Resource Allocation
  • Importance of Thought Leader Management Activities
  • Managing Thought Leader Interactions
  • Effectiveness of Coordination Methods
KEY METRICS
  • Leadership for Thought Leader Management
  • Functional and Budget Responsibility for Thought Leader management
  • Challenges and Success Factors in Developing and Maintaining Strong Thought Leader Management
  • Thought Leader Spend as Percent of Total Medical Affairs Spend
  • Percentage of the Total Thought Leader Management Spend Allocated to Listed Activities
  • Importance of Thought Leader Services to the Success of the Organization
  • Tactics to Overcome Access Challenges
  • Approaches Employed to Coordinate Thought Leader Management Resources Across Functions to Avoid Redundancy or Confusion
  • Increasing the Effective Use of CRM Tools
  • Effectiveness of Coordination Methods


SAMPLE KEY FINDINGS

  • Thought Leader Management Functions are Becoming Critical: Thought Leader Management groups have a director or higher level leadership. This demonstrates the importance of the Thought Leader Management function for biopharmaceutical companies.
  • Budget and Functional Responsibilities Should Align: Ideally, companies should align budget management and functional responsibilities to use resources effectively. While Medical Affairs group leads Thought Leader Management in a majority of the companies, the group has less budget decision power than functional responsibility in this area.

METHODOLOGY

Thirty-one survey responses from Medical Affairs leaders at 27 biopharmaceutical companies. This report captures insights on Large , Mid-Size and Small companies segments as well as on companies from Global and US-only regions.

Industries Profiled:
Biopharmaceutical; Biotech; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Medical Device; Chemical; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alkermes; Allergan; Baxalta; Bayer; Celldex Therapeutics; CSL Behring; Genentech; Genzyme; GW Pharmaceuticals; Indivior; Jazz Pharmaceuticals; Mesoblast; Neurocrine Biosciences; Norgine; Novo Nordisk; Perrigo Company; Pfizer; ProStrakan; Sanofi; Santen; Shire; Stallergenes; Sunovion; Teva Pharmaceutical Industries Ltd; Theravance; Tris Pharma; UCB Pharma


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.